Dosage of oligonucleotides suitable for the treatment of tumors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8822425
APP PUB NO 20100286236A1
SERIAL NO

12453487

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method for preventing and/or treating a tumor, the method comprising: intravenously administering an antisense oligonucleotide in an amount of between about 400 to about 800 mg/m2/treatment cycle, the antisense oligonucleotide comprises 8 to 30 nucleotide building blocks, which hybridizes with mRNA of TGF-beta-2, -1 and/or -3 for the preparation of a pharmaceutical composition.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ANTISENSE PHARMA GMBHJOSEF-ENGERT-STRASSE 9 REGENSBURG D-93053

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Heinrichs, Hubert Regensburg, DE 1 13
Schlingensiepen, Karl-Hermann Donaustauf, DE 23 258
Schmaus, Susanne Grossberg-Pentling, DE 1 13

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 2, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00